NCT02355535View on ClinicalTrials.gov

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

May 18, 2020

Study Completion Date

May 18, 2020

Conditions
Solid TumorPancreatic Neuroendocrine TumorNeuroendocrine Tumors
Interventions
DRUG

PAC-1

PAC-1 is taken orally on days 1-21 of a 28-day cycle.

Trial Locations (3)

21231

Johns Hopkins Kimmel Cancer Center, Baltimore

55101

Regions Hospital, Saint Paul

60612

University of Illinois at Chicago, Chicago

All Listed Sponsors
collaborator

University of Illinois at Chicago

OTHER

lead

Vanquish Oncology, Inc.

INDUSTRY

NCT02355535 - Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | Biotech Hunter | Biotech Hunter